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Background: Because of the need to limit side-effects, nanoparticles are increasingly being studied as drug-carrying
and targeting tools. We have previously reported on a scheme to produce protein-based self-assembling nanoparticles
that can act as antigen display platforms. Here we attempted to use the same system for cancer-targeting, making use
of a C-terminal bombesin peptide that has high affinity for a receptor known to be overexpressed in certain tumors, as
well as an N-terminal polyhistidine tag that can be used for radiolabeling with technetium tricarbonyl.
Results: In order to increase circulation time, we experimented with PEGylated and unPEGylated varities typo particle.
We also tested the effect of incorporating different numbers of bombesins per nanoparticle. Biophysical
characterization determined that all configurations assemble into regular particles with relatively monodisperse size
distributions, having peaks of about 33 – 36 nm. The carbonyl method used for labeling produced approximately 80%
labeled nanoparticles. In vitro, the nanoparticles showed high binding, both specific and non-specific, to PC-3 prostate
cancer cells. In vivo, high uptake was observed for all nanoparticle types in the spleens of CD-1 nu/nu mice, decreasing
significantly over the course of 24 hours. High uptake was also observed in the liver, while only low uptake was seen in
both the pancreas and a tumor xenograft.
Conclusions: The data suggest that the nanoparticles are non-specifically taken up by the reticuloendothelial system.
Low uptake in the pancreas and tumor indicate that there is little or no specific targeting. PEGylation or increasing the
amount of bombesins per nanoparticle did not significantly improve targeting. In particular, the uptake in the spleen,
which is a primary organ of the immune system, highlights the potential of the nanoparticles as vaccine carriers. Also,
the decrease in liver and spleen radioactivity with time implies that the nanoparticles are broken down and cleared.
This is an important finding, as it shows that the nanoparticles can be safely used as a vaccine platform without the risk
of prolonged side effects. Furthermore, it demonstrates that technetium carbonyl radiolabeling of our protein-based
nanoparticles can be used to evaluate their pharmacokinetic properties in vivo.
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There is a growing interest in nanoparticles and their
various applications [1-4]. It is assumed that nanoparti-
cles would bring about a better target to non-target ratio
of drug uptake in drug delivery approaches. An interest-
ing way to produce nanoparticles is the use of polypep-
tides, which are present in folded or unfolded form,
depending on the nature and concentration of a salt in
aqueous solution. The crucial point is that such peptides
are selected, which stick together during the folding process
in a well-defined amount and thus form a spherical nano-
particle [5]. We have used coiled-coil domains as build-
ing blocks to engineer self-assembling protein nanoparticles
(SAPN) [6-8]. Such proteins can be produced with gen-
etically engineered cells and can be extended at the N or
C-terminus with freely selectable amino acid residues.
If the peptide sequence of a known antigen is used, for-
mation of the nanoparticle will result in the repetitive
display of that antigen. We have used this concept to
produce promising vaccine candidates for illnesses such
as influenza, malaria, SARS, and HIV [9-12].
Here we tried to use the same system to develop nano-
particles for drug targeting and medical imaging. The
N-terminus of the peptide chain usually comprises six
histidines, a so-called His-tag, which is used to separate
the engineered peptide on a Ni-NTA-column. The
His-tag is not only a chelator for Ni on the column
but has a high affinity for the Technetium tricarbonyl
as well, and thus, it can be used for labeling with the
Technetium carbonyl method [13-15]. At the C-terminus,
in addition to linkers, we have introduced Asn-Gln-
Trp-Ala-Val-Gly-His-Leu-Met, namely bombesin (BN)
(residues 6–14). Bombesin was selected because it is
known to have a high affinity to the GRP receptor, which
is over-expressed in many tumors. Moreover, we have
investigated the free bombesin peptide for many years
[16,17]. Radiotracers consisting of biologically active
compounds and radionuclides are powerful tools in
three different areas of medical applications [18-21],
namely diagnosis, therapy, and drug development. The
latter gained increasing interest since the introduction
of a radiolabeled drug analogue to study a limited num-
ber of patients or healthy volunteers gives insight into
the properties and behavior of a drug in humans. Gener-
ally, positron emitters such as C-11 (at the place of C-12)
or F-18 (substituting stable -H or -OH) are used for this
purpose because the quantification of the organ uptake is
much easier with positron emission tomography (PET)
than with single-photon emission computed tomography
(SPECT). However, the radiation burden with PET is
rather high and considerable reduction could be achieved if
a Technetium-99 m (99mTc) labeled analogue was applied.
The goal of this study was to assess the biodistribution of
radionuclide-labeled self-assembling protein nanoparticlesin a tumor mouse model. To this aim the protein chain
of the nanoparticle was modified with the tumor target-
ing peptide bombesin and then co-assembled with the
same protein chain without bombesin at different ratios.
Nanoparticles are known to be trapped in the reticulo-
endothelial system (RES), mainly in the liver like the la-
beled colloids, which have been introduced in the nuclear
medicine long ago. Since this elimination from the blood
stream strongly hampers the uptake into other target
tissues we also introduced poly(ethylene glycol) (PEG)
coated particles, an approach that has previously suc-
cessfully been used [22,23]. Radioactive technetium was
then attached to the His-tag of the protein and the bio-
distribution was assessed in a mouse model (Figure 1).
No increased accumulation of the radioactivity could be
observed in tumor cells, even when the particles were
PEGylated. However, the biodistribution strongly indicates
that these nanoparticles are ideal vaccine candidates as
they significantly accumulate in the spleen, which plays
an important role in the immune system. These results
support our previous findings [9-12], which demonstrate
the nanoparticles’ ability to act as effective vaccines.
Results
SAPN design
We wanted to test whether there was a difference in the
biodistribution of the nanoparticles based on different
density of the targeting peptide bombesin and different
coupling modalities of PEG to the nanoparticles. Figure 2
shows the amino acid sequences of the three different
peptides used in this study. The density of bombesin was
varied by co-assembly of P6c (or P6c-PbK) with P6c-BN
at different ratios (Table 1), while the PEG moiety was
either attached to P6c or P6c-PbK. Both P6c and P6c-PbK
peptides have two primary amine groups (α-NH2 from the
methionine residue, and ε-NH2 from the lysine 12 in P6c
and lysine 127 in P6c-PbK, respectively, all depicted in
orange in Figure 2) in each chain. However, the lysine
side chain in P6c is located between two bulky trypto-
phan residues and might therefore not be accessible
enough for efficient coupling of the PEG moiety. Also,
in P6c the two coupling sites are both located on the
N-terminal end of the nanoparticle peptide chain. There-
fore, in the P6c-PbK peptide the lysine coupling site was
engineered to the C-terminus at the Therefore, in the P6c-
PbK peptide the lysine coupling site was engineered to the
C-terminus at the very end of a peptide surface modifica-
tion (GGSGDPPPPNPNDPPPPNPND) that previously
produced very nice nanoparticles [24], hence it was moved
from a less exposed site on the N-terminus to a well-
exposed site on the C-terminus. It was expected that in
the P6c-PbK design the coupling efficiency is higher
and that the PEG moiety is more surface exposed on
the nanoparticles.
Figure 1 Schematic drawing of the co-assembly of the protein chains to multi-functional nanoparticles and the radio-labeling experiments.
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In an attempt to increase the SAPN circulation time, we
used PEGylated versions of the nanoparticle forming
peptides. The P6c and P6c-PbK peptides were PEGylated
using methoxyl PEG succinimidyl ester (mPEG-NHS) in
denaturing conditions. The N-hydroxylsuccinimide (NHS)
functional group reacts with the primary amine groups
in the peptides. SDS-PAGE was used for analyzing the
PEGylation products, as shown in Figure 3. The P6c
PEGylation products have an extra band that ran slightly
above the P6c monomer band (Figure 3, left panel, lane
C), which indicated that some of the P6c peptide chains
were PEGylated. The PEGylation ratio is about 30-50% by
estimating the intensity of the two bands. As shown in
Figure 3, right panel, the unPEGylated (lane E) and the
P6c-PbK PEGylation (lane F) products showed similar
results, except the extra band that ran above the P6c-
PbK monomer band after PEGylation. This extra band
is the trimeric form of the protein because it forms a
stable coiled-coil even under the strongly denaturing
conditions of the SDS-PAGE. The PEGylation ratio for
the P6c-PbK peptide is also about 30-50 % by estimating
the intensity of the two bands. The PEGylation reactionFigure 2 Peptide sequences used. Green = pentamer, Blue = trimer, Red
for PEGylation.often produces a mixture of heterogeneous PEGylated
compounds. It is difficult to determine the number and
location of the PEG molecules from the SDS-PAGE
analysis, and hence it is also difficult to detect a differ-
ence in the coupling efficiency between the two peptide
chains.
Particle size distribution
When the particles were refolded using a stepwise proced-
ure, dynamic light scattering showed a size distribution
with a peak of about 35 nm (Figure 4). All 3 PEGylated
samples had size distributions with surprisingly similar
peak diameters. Transmission electron microscopy (Figure 5)
confirmed that regular, spherical particles with sizes in
this range formed. It is also apparent, however, that
PEGylation led to staining artifacts in the image.
Radiolabeling
The labeling procedure with the carbonyl method was not
optimized and yielded up to 80 % of labeled particles. The
impurities were not identified, however, the chromato-
gram obtained during purification showed both small
and large impurities. The small ones were of similar size= bombesin, Black = linkers and His-tag, Orange = amino groups used
Table 1 Refolding ratios of the different peptides without BN and P6c-BN
Refolding trial P6c P6c-PEG P6c-PbK-PEG P6c-BN Name
1 0 0 50 10 P6c-PbK-PEG/P6c-BN 50:10
2 0 0 40 20 P6c-PbK-PEG/P6c-BN 40:20
3 0 50 0 10 P6c-PEG/P6c-BN 50:10
4 50 0 0 10 P6c/P6c-BN 50:10
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particles. The labeled particles were stable for at least one
day, corresponding to four half live times of 99mTc.In vitro properties
The in vitro studies showed the same pattern in all ex-
periments, namely a high total binding to the cells and
an equally high non-specific binding. As a consequence
the specific binding (difference of total and non-specific
binding) reflected only the statistical error of the experi-
mental data.In vivo properties
The biodistribution (Figure 6 and Table 2) showed high
uptake in the liver and the spleen, which was quite simi-
lar at 1 h and 4 h post injection, while a clear decline
was seen at 24 h. Roughly 80% (± 10%) of the injected
activity was trapped in the liver (Figure 6). Since the
weight of the liver showed inter-animal variation between
650 and 1200 mg, concentrations from 60% up to 140%
injected dose per g tissue were obtained (Table 2). TheFigure 3 SDS-PAGE analysis of the PEGylation products. Left, the
P6c peptide: A) Mw Marker B) uncoupled C) coupled with PEG; Right,
the P6c-PbK peptide: D) Mw Marker E) uncoupled; F) coupled with
PEG. For both constructs also the trimer band is visible on the gel.uptake per whole spleen was only 1% of the injected
dose in the case of P6c-PbK-PEG/P6c-BN 50:10; a slight
increase at 4 h and decrease at 24 h post injection were
seen (Figure 6). A diverging behavior concerns the time
course of the % ID/g (Table 2). There the Tc-labeled
P6c-PbK-PEG/P6c-BN 50:10 decreases strongly from
21% ID/g (at 1 h) to 9% ID/g (at 24 h). The reason is the
variable weight of the spleen. In most experiments
animals with light and heavy spleens were rather uni-
formly distributed among the type of particles and time
points. Only in the case of P6c-PbK-PEG/P6c-BN 50:10
it happened that the ''1 h group'' had light spleens (aver-
age 77 g) while the ''24 h group'' had rather heavy spleens
(average 121 g). The other three types of particles showed
an uptake of 3% (± 1 %) at 1 h post injection. Specific
bombesin mediated uptake would show elevated values
of 99mTc activity in the pancreas and the tumor. How-
ever, in agreement with the in vitro data this was not
observed. The uptake in the stomach and colon was
low, very close to that of the intestine at all time points.
PEGylation did not appear to significantly affect the
biodistribution.
Discussion
Nanoscale assemblies represent a new and interesting
approach to the development of vaccine technology. In
particular, protein-based assemblies are an attractive
choice for a vaccine platform because of their safety and
flexibility of design [4]. The SAPN system we utilized in
this work has the additional benefits of being easy to
produce, biophysically well characterized [6-8], and able
to elicit a response against even poorly immunogenic
peptides [25]. Consequently, we have successfully used
SAPNs as vaccines against a number of important dis-
eases [9-12].
Genetically engineered protein nanoparticles and radi-
olabeling of their His-tag are tools to prepare particles of
uniform size and to study the in vivo behavior. The
nanoparticles showed a rather monodisperse size distri-
bution that was not affected by coupling of PEG to the
nanoparticles. The uptake pattern in liver and spleen
(Figure 6) reflects a non-specific uptake in the RES, which
is mainly depending on the size and maybe on the lipophi-
licity/hydrophilicity of the particle surface. Tröster et al.
[26] have shown that lower spleen uptake correlates with
higher lipophilicity. Surprisingly, we observed exactly
Figure 4 Size distributions of different nanoparticle coassemblies as measured by dynamic light scattering. Black: P6c/P6c-BN 50:10
(Peak = 36.4 nm). Blue: P6c-PEG/P6c-BN 50:10 (Peak = 34.8 nm). Red: P6c-Pbk-PEG/P6c-BN 50:10 (Peak = 32.8 nm). Green: P6c-Pbk-PEG/P6c-BN
40:20 (Peak = 33.1 nm).
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P6c-PbK was less accumulated in the spleen than P6c
(Figure 6). The peptide GGSGDPPPPNPNDPPPPNPNDK
carries four charges and is quite hydrophilic. Furthermore,
when incorporating a higher proportion of the hydropho-
bic bombesin into the nanoparticle, uptake in the spleen
was increased.
While the liver uptake was around 80% of the injected
dose 1 h after injection and showing virtually no vari-
ation, the uptake in the spleen was around 3% of the
injected dose and considerably lower (1%) with the P6c-
PbK-PEG/P6c-BN 50:10 particles. The observed uptake
is quite similar to the distribution observed with 99mTc
labeled colloidal preparations, which is attributed to
the properties of the RES. Depending on the nature ofFigure 5 Transmission electron microscopy of PEGylated samples.
C) P6c-PEG/P6c-BN 50:10.the colloids basically the size of the particles, increased
uptake in either liver, spleen or bone marrow was seen.
The uptake in the liver is quite high as would have been
expected for protein-based materials. Unfortunately, the
uptake could not be reduced by PEGylation of the nano-
particles but stays roughly the same for all the prepara-
tions used in this study.
The washout of the activity from liver and spleen can
be interpreted as a degradation of the particles, which is
well in agreement with the biological function of these
organs. The total activity cleared via kidneys and urine
could not be determined, however the activity concen-
tration in the urine was generally around 10 to 20% of
the injected dose per ml urine. Since the intact particles
are roughly ten times larger than compounds, whichA) P6c-Pbk-PEG/P6c-BN 50:10. B) P6c-Pbk-PEG/P6c-BN 40:20.
Figure 6 Uptake in the liver (top) and spleen (bottom) expressed as % of the injected activity per whole organ at different times
after injection.
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4 nm diameter), this clearance must be due to broken
down particles and short peptide chains. Another possibil-
ity would be simply a decomposition of the Tc-complex.
However, if only the Tc-complex would be destroyed, the
free Tc would be oxidized rapidly to pertechnetate which
subsequently would lead to an increased uptake in the
stomach. Such uptake was not observed. The in vitro tests
showed a high binding to the cells, which increased with
time. This time course was slightly different depending on
the nature of the nanoparticles. However, no experiment
showed any specific uptake, which could be attributed to
the bombesin moieties on the particle surface.Conclusions
We have shown that self-assembling protein nanoparticles
accumulate in the immune organ spleen and therefore
have the potential to be very immunogenic, supporting
our earlier research using SAPNs as vaccines. Our study
also shows that the nanoparticles might be safely applied
as the metabolism and elimination at least indicates
that no long-term problems must be considered. In this
respect we have also shown that radiolabeling of nano-
particles is a tool with high potential for performing
pharmacokinetic studies of such nanoparticle vaccines.
It should be noted that the originally planned application
of the SAPNs presented here, namely drug targeting and
Table 2 Biodistribution*
P6c/P6c-BN 50:10 P6c-PEG/P6c-BN 50:10 P6c-PbK-PEG/P6c-BN 50:10 P6c-PbK-PEG/P6c-BN 40:20
Organ 1 h 4 h 24 h 1 h 4 h 24 h 1 h 4 h 24 h 1 h 4 h 24 h
Blood 0.31(4) 0.25(8) 0.13(2) 0.5(1) 0.42(6) 0.17(2) 0.4(1) 0.4(1) 0.15(1) 0.33(2) 0.27(3) 0.14(1)
Heart 0.16(4) 0.13(2) 0.09(4) 0.20(4) 0.21(4) 0.12(4) 0.25(6) 0.21(4) 0.15(3) 0.21(3) 0.18(3) 0.15(5)
Lung 6(1) 2.8(7) 0.9(4) 4.8(3) 5(2) 1.0(2) 2.9(7) 1.8(3) 0.9(1) 6(3) 2.5(2) 1.01(2)
Spleen 37(10) 31(7) 19(4) 43(11) 27(6) 18(4) 21(3) 22(5) 9(1) 32(6) 33(8) 20(4)
Kidneys 2.5(2) 3.8(9) 4.5(1) 3.8(3) 7.4(9) 7(1) 3.0(8) 4.4(8) 3.5(3) 3.3(3) 4.3(1) 5.1(4)
Pancreas 0.4(6) 0.3(1) 0.05(5) 2(2) 0.23(1) 0.3(1) 0.17(5) 0.4(3) 0.3(2) 1(1) 1.1(9) 0.12(7)
Stomach 0.6(7) 0.26(2) 0.20(3) 0.8(1) 0.5(2) 0.27(7) 0.3(2) 0.3(2) 0.17(6) 0.8(4) 0.38(5) 0.24(7)
Intestines 0.23(4) 0.22(4) 0.21(6) 0.33(5) 0.26(2) 0.20(5) 0.4(2) 0.44(3) 0.25(5) 0.6(2) 0.34(6) 0.3(1)
Colon 0.25(9) 0.22(5) 0.3(1) 0.3(1) 0.30(7) 0.22(5) 0.25(6) 0.4(2) 0.15(4) 0.3(1) 0.26(3) 0.21(2)
Liver 78(7) 68(4) 40(11) 67(6) 66(5) 49(12) 103(34) 85(13) 38(3) 77(9) 73(17) 49(2)
Muscle 0.19(6) 0.12(4) 0.16(6) 0.6(4) 0.3(3) 0.2(1) 0.4(2) 0.3(2) 0.2(1) 0.9(5) 0.6(2) 0.09(1)
Bone 2.5(8) 1.6(5) 1.3(7) 3(1) 1.8(2) 1.6(4) 3(2) 1.9(5) 0.8(2) 2(1) 2.8(6) 1.5(3)
Tu (av) 0.12(2) 0.13(4) 0.13(6) 0.2(1) 0.2(1) 0.2(1) 0.16(6) 0.18(7) 0.09(4) 0.2(1) 0.13(2) 0.11(4)
Bile 6.6(7) 3(2) 9(7) 12(12) 8(7) 4(2) 8(3) 12(4) 15(10) 10(10) 12(8) 13(11)
Urine 19(10) 30(24) 21(2) 39(8) 57(9) 14(2) 23(20) 111(10) 17(2) 27(4) 30(5) 9(5)
*Data represent % injected dose per g tissue of four differently substituted SAPN at different time points after injection (the error of the last digit in parentheses).
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The peptides P6c [6,8], P6c-PbK and P6c-BN consist of
a pentameric coiled-coil domain derived from cartilage
oligomeric matrix protein (COMP) [27], linked to a trimeric
coiled-coil domain that was de novo designed [28,29]. The
P6c peptide has a His-tag sequence (22 amino acids, black)
at the N-terminus, followed by a pentameric domain (36
amino acids, green) and a trimeric domain (46 amino acids).
The P6cPbK peptide was created based on the P6c pep-
tide, but with a lysine residue at its C-terminus. In the
peptide P6c-BN, the sequence was extended at its C-
terminal end with a flexible linker (GSGSGSGSGS) and
nine residues (NQWAVGHLM) from the peptide bom-
besin. The sequences of P6c, P6c-PbK and P6c-BN are
shown in Figure 2.
Transformation
Plasmids carrying the genes for P6c and P6c-BN were
transformed into competent BL21(DE3) pLysS E. Coli
cells (Novagen, Madison, WI) by adding 5 μL plasmid to
100 μL cells. After allowing the mixture to cool on ice
for 30 minutes, the cells were treated with a heat shock
at 42°C for 90 seconds. After cooling the cells on ice for
2 minutes, 800 μL SOC medium were added and the
cultures grown at 37°C, under shaking at 300 RPM, for45 minutes. 100 μL of the cultures were spread on
LB-agar plates containing 100 μg/mL ampicillin and
30 μg/mL chloramphenicol and left overnight at 37°C.
Peptide expression and purification
Peptides were expressed by inoculating 50 mL Luria
broth containing 100 μg/mL ampicillin and 30 μg/mL
chloramphenicol with a single, isolated colony from the
transformation plate. The culture was grown overnight
at 37°C. The following day, 30 mL were used to inocu-
late 3 L of Luria broth containing 100 μg/mL ampicillin
and 30 μg/mL chloramphenicol. The cells were allowed
to grow at 37°C, under shaking at 180 RPM, until the
OD600 = ~0.5. Expression was induced by addition of iso-
propyl β-D-thiogalactopyranoside. The cells were grown
for an additional 4 hours and harvested by centrifugation
at 4,000 RPM for 15 minutes. Cell pellets were stored
at −20 °C until purification.
Cells were resuspended in lysis buffer (9 M urea, 10 mM
Tris pH 8.0, 100 mM NaH2PO4) and lysed by sonication.
The lysates were clarified by centrifugation at 30,500xg
for 45 minutes. Cleared lysate was then passed through
a nickel affinity column (GE Healthcare, Waukesha, WI),
which was washed first with lysis buffer then with high
phosphate buffer (9 M urea, 10 mM Tris pH 8.0, 500 mM
NaH2PO4, 20 mM imidazole). The column was then
washed with 9 M urea, 20 mM citrate, 100 mM NaH2PO4,
20 mM imidazole, at three different pH values: 6.3, 5.9,
and 4.3. Finally, the column was washed with lysis buffer
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of the collected fractions was determined by SDS PAGE.
The purified peptide was then dialyzed into imidazole-
free buffer: 8 M urea, 20 mM Tris pH 7.5, 150 mM
NaCl, 2 mM EDTA.
PEGylation of P6c and P6c-PbK
The PEGylation agent mPEG-NHS (1 kDa) was purchased
from Nanocs, Inc., New York, USA. The peptides were
concentrated to 1–5 mg/ml in a buffer containing 50 mM
sodium phosphate, pH7.5, 0.05% SDS. Then the mPEG-
NHS powder was added to the concentrated peptide solu-
tion in 50 mM sodium phosphate, pH 7.5, 0.05% SDS and
incubated with 1000 rpm shaking at room temperature.
In the reaction mixture, the molar ratio of mPEG-NHS
to peptide was about 100:1. After the PEGylation reaction,
the excess of mPEG-NHS was removed using a dialysis
membrane with MWCO of 6000–8000 kDa (Spectrum
Laboratories, Inc., CA, USA). The product mixture was
analyzed using SDS-PAGE. They were used without fur-
ther purification.
Refolding
For the un-PEGylated particles, the two peptides P6c
and P6c-BN were first dialyzed into a denaturing buffer
(8 M urea, 20 mM Hepes pH 7.5, 150 mM NaCl, 5% gly-
cerol) then filtered with a 0.1 μm filter (Millipore, Billerica,
MA). They were then mixed so that the ratio of moles P6c
to moles P6c-BN was 50:10. The mixed peptide solution was
then diluted with filtered denaturing buffer such that the
final peptide concentration was approximately 0.1 mg/ml.
Refolding was done by stepwise dialysis into buffers with
20 mM Hepes pH 7.5, 150 mM NaCl, 5% glycerol and
successively lower urea concentration. The steps were: 6,
4, 2, 1, 0, 0 M urea. 0 M urea was used twice to ensure re-
moval of any residual urea.
For the PEGylated samples the PEGylated products from
the previous steps were directly used for co-assembling
with unPEGylated P6c-BN without further purification.
The PEGylated products were filtered and then denatured
in the same denaturing buffer as is described above. They
were then mixed to the appropriate molar ratios with
unPEGylated P6c-BN (Table 1) and diluted to approxi-
mately 0.1 mg/ml. Refolding was performed by direct
dialysis into 0 M urea buffer. The 0 M urea step was
performed twice to remove residual urea.
Dynamic light scattering
Dynamic light scattering experiments were carried out on
a Zetasizer Nano S Instrument (Malvern, Worcestershire,
UK), with a 633 nm He-Ne laser. All measurements were
carried out at 25°C in 20 mM Hepes pH 7.5, 150 mM
NaCl, 5% glycerol.Transmission electron microscopy
Samples were negatively stained with 1% uranyl acetate
(SPI Supplies, Westchester, PA, USA) and observed with
a FEI Tecnai T12 S/TEM at an accelerating voltage of
80 kV (FEI, Hillsboro, Oregon).
Labeling with 99mTc
Labeling with 99mTc was done in two steps. First, 1 ml of
[99mTc]pertechnetate, obtained from a Mo/Tc-Generator
(Ultratechnecow, Mallinckrodt), was added to a mixture
of 4.5 mg sodium boranocarbonate, 2.9 mg borax and
9 mg sodium potassium tartrate and heated at around
95°C for 20 min. The obtained solution with [Tc(CO)3
(H2O)3]
+ was cooled to room temperature, neutralized
with hydrochloric acid and buffered with phosphate
buffer at pH 6–7. In a second step 10 – 50 μl of this
solution (depending on the activity concentration of the
generator eluate) was mixed with 0.1 ml of a suspension
of 0.8 mg/ml of the respective SAPN and kept at 40–50°C
for 1 h. After cooling, the final product was purified over a
PD10 column since the labeling yield was only up to 80%.
Two flow-through cells, one equipped with an UV de-
tector, the other with a radioactivity detector, were used
to analyze the eluate.
Cell line for pharmacological tests
The human prostate adenocarcinoma cell line PC-3 was
obtained from the European Collection of Cell Culture
(CRL-1687, ECACC; Salisbury, England). The cells were
maintained in DMEM GLUTAMAX-I supplemented
with 10% FCS, 100 IU/mL penicillin G sodium, 100 μg/mL
streptomycin sulfate and 0.25 μg/mL amphotericin B. The
cells were incubated at 37°C in an atmosphere containing
5% CO2 and twice weekly subcultured after detaching with
trypsin/EDTA (0.25%).
Internalization studies
For internalization, PC-3 cells at confluence were placed
in 6-well plates and left to attach overnight. Cells were
incubated with the labeled analogues (4 kBq) in culture
medium for 0.5, 1, 2, 4 and 24 h at 37°C (final volume
1 mL/well). Nonspecific binding was determined with
10 μM unlabeled BN (residues 1–14) or unlabeled parti-
cles. After the different incubation times, cells were
washed twice with cold PBS to discard unbound peptide.
Surface-bound activity was removed by a 5-min acid
wash (50 mM glycin-HCl, 100 mM NaCl, pH 2.8), which
was twice applied at room temperature. Afterwards,
the plates were washed with cold PBS and the cells
were lysed with 1 M NaOH twice. Surface-bound and
internalized radioactivity was measured in the gamma
counter. Additional experiments were carried out with
internalization inhibitors, such as sucrose 0.4 mM,
Phenylarsinoxid 0.01 mM, Methyl-β-cyclodextrin 10 mM,
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0.05 mM.
Binding test
PC-3 cells were placed at different concentrations (0.0625 –
2 million cells/well) in 12-well plates. They were incubated
for 2 h at 37°C with 20 kBq 99mTc labeled SAPN-BN
(250 μl). Nonspecific binding was determined in presence
of 1 μmol/l unlabeled bombesin (1–14). After incubation
the supernatant was discarded and the cells washed twice
with PBS. To detach the cells the wells were washed 2
times with 500 μl 1 N NaOH and the activity measured in
a -counter.
Biodistribution studies
All animal experiments were conducted in compliance
with the Swiss animal protection laws and with the ethical
principles and guidelines for scientific animal experi-
mentation established by the Swiss Academy of Medical
and Natural Sciences. Biodistribution studies were per-
formed with 6- to 8-week-old female CD-1 nu/nu mice
(20–25 g) purchased from Charles River Laboratories
(Sulzfeld, Germany). For the induction of tumor xenografts,
each mouse received subcutaneously 8x106 PC-3 cells in
150 μL culture medium without supplements. The tumors
were allowed to grow for at least three weeks. On the day
of the experiment, the mice (3 per group) received the
labeled nanoparticles intravenously. At 1, 4 and 24 h
post injection (p.i.), the animals were euthanized and
dissected. Blood, tumors and various healthy tissues and
organs were collected and weighed. The amount of
radioactivity in each tissue was determined by measuring
the samples with the gamma counter and decay corrected
(reference time = time of injection). Results are expressed
as percentage of injected dose per gram of tissue (%ID/g).
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